- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00982553
The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
A Prospective, Open-label, Three Phase Pharmacokinetic Study, to Assess the Pharmacokinetic Profile and Safety of Raltegravir 400 mg Twice Daily and Ribavirin 800 mg Once Daily, When Dosed Separately and Together in Healthy Volunteers
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Phase I (study day 1 - 14):
- 14 healthy volunteers with a documented negative HIV-1 antibody test during screening procedures will be enrolled.
- On day 1, fasted subjects will be administered ribavirin 800 mg without food (witnessed dosing). This will be followed be a 12 hour detailed pharmacokinetic assessment; blood sampling drawn at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12 hours.
- This will be followed by a wash-out period.
- As steady state pharmacokinetics of ribavirin are not reached for several weeks, single dosing pharmacokinetics will be assessed in this study
Phase II (study days 15 - 19):
- On day 15, subjects will commence raltegravir 400 mg twice daily. Subjects will attend for safety visits and witnessed dosing during this phase.
- Day 19 - after 4 days of dosing when steady state pharmacokinetics has been reached, subjects will attend for a 12 hour detailed pharmacokinetic visit where following witnessed administration of raltegravir 400 mg without food, blood sampling will be drawn at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 and 12 hours post dose for the assessment of raltegravir plasma exposure.
Phase III (study day 20):
• Subjects will be administered raltegravir 400 mg and ribavirin 800 mg without food. This will be followed by a 12 hour detailed pharmacokinetic assessment with blood sampling drawn at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, and 12 hours.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
-
London, Storbritannien, W2 1NY
- Imperial College Healthcare NHS Trust
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements.
- Male or non-pregnant, non-lactating female.
- Between 18 to 60 years, inclusive.
- Subjects in good health upon medical history, physical exam, and laboratory testing and body mass index below 32.
Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study including 180 days following last dose of study drug:
- barrier contraceptives (condom, diaphragm with spermicide)
- oral combined contraceptive pill, implant or injectable hormonal contraceptive PLUS a barrier contraceptive
- Intrauterine device (IUD) or intrauterine system (IUS) PLUS a barrier contraceptive (or a partner who has been vasectomized for at least six months).
- Female subjects of childbearing potential must have a negative urine pregnancy test.
- Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study including 180 days following last dose of study drug.
- Have no serologic evidence of HIV infection.
- Have no serologic evidence of active hepatitis B virus infection evidenced by negative hepatitis B surface antigen and no serologic evidence of hepatitis C virus infection through antibody testing.
- Have screening laboratory results (haematology, chemistry) that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the Investigator to have no clinical significance.
Exclusion Criteria:
- Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy.
- Have a body mass index (BMI) greater than 32
- Previous participation in an investigational trial involving administration of any investigational compound within 1 month prior to the study screening.
- Clinically relevant alcohol or drug use (positive screening drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study.
- Any medication taken listed in Prior and Concomitant Medication section including over-the-counter medications and herbal products within 21 days of commencing study drug dosing with the exception of vitamins and/or paracetamol and/or hormonal contraceptives including the combined oral contraceptive pill, Depo-Provera and the Mirena intrauterine system. When a concomitant medication is necessary, this will be reviewed by the Investigator and if not contraindicated, may be continued at the same dose and frequency during the study period.
- History of drug sensitivity or drug allergy.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Phase 1_ribavirin
Treatment with Single dose ribavirin (800 mg) administered on day 1
|
800mg once daily
Andra namn:
|
Experimentell: Phase2_raltegravir
Treatment with Raltegravir (400 mg twice daily) administered from days 15-19
|
400 mg två gånger dagligen
|
Experimentell: Phase3_ribavirin+raltegravir
Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20
|
400 mg två gånger dagligen
800mg once daily
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Ribavirin Maximum Plasma Concentration
Tidsram: Day 20
|
Pharmacokinetic analyses of blood samples
|
Day 20
|
Raltegravir Maximum Plasma Concentration
Tidsram: Day 20
|
Day 20
|
|
Ribavirin Minimum Plasma Concentration
Tidsram: Day 20
|
Ribavirin minimum plasma concentration by pharmacokinetic analyses
|
Day 20
|
Raltegravir Minimum Plasma Concentrations
Tidsram: Day 20
|
Raltegravir minimum plasma concentrations by pharmacokinetic analyses
|
Day 20
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Alan Winston, MB BH, Imperial College London
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- HIV-infektioner
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Antimetaboliter
- HIV-integrashämmare
- Integrashämmare
- Ribavirin
- Raltegravir kalium
Andra studie-ID-nummer
- 2009-010005-36 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
Kliniska prövningar på Raltegravir
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AvslutadHIV-infektionerFörenta staterna, Puerto Rico, Sydafrika, Argentina, Brasilien, Botswana
-
ViiV HealthcareAvslutadInfektion, humant immunbristvirusFörenta staterna
-
Merck Sharp & Dohme LLCAvslutad
-
Bristol-Myers SquibbMerck Sharp & Dohme LLCAvslutad
-
ViiV HealthcareGlaxoSmithKline; ShionogiAvslutadHIV-infektioner | Infektion, humant immunbristvirusFörenta staterna, Frankrike, Nederländerna, Spanien, Taiwan, Australien, Belgien, Ryska Federationen, Kanada, Storbritannien, Mexiko, Italien, Sydafrika, Rumänien, Argentina, Ungern, Polen, Chile, Grekland, Brasilien
-
ANRS, Emerging Infectious DiseasesAvslutadHIV-1-infektion | GRAVIDITETFrankrike
-
ViiV HealthcareGlaxoSmithKline; ShionogiAvslutadInfektion, humant immunbristvirus ITyskland, Spanien, Frankrike, Australien, Förenta staterna, Kanada, Storbritannien, Italien, Ryska Federationen
-
Universidad Peruana Cayetano HerediaMerck Sharp & Dohme LLCAvslutadHTLV-I-infektioner | Tropisk spastisk paraparesPeru
-
National Institute of Allergy and Infectious Diseases...AvslutadHIV-infektioner | TuberkulosSydafrika